JAMA

09/03/2025

FDA-identified uncertainties in clinical trials for new cancer drugs are frequently underreported in journal publications and clinical guidelines, potentially leaving clinicians unaware of critical trial limitations.

https://ja.ma/3JQvbNP

09/03/2025

Methamphetamine is a central nervous system stimulant that blocks uptake and increases release of norepinephrine, serotonin, and dopamine, causing euphoria, wakefulness, and increased attention.

This JAMA Insights discusses the health consequences of methamphetamine use and recommends comprehensive care strategies, including harm reduction, behavioral therapies, and the use of off-label medications to treat methamphetamine use disorder.

https://ja.ma/4ncNzyH

09/03/2025

Untreated hypothyroidism can cause serious health complications such as heart failure and myxedema coma.

Author Maria Papaleontiou, MD, of the University of Michigan joins JAMA Senior Editor Karen Lasser, MD, MPH, to discuss the current evidence regarding the epidemiology, diagnosis, clinical presentation, and treatment of primary overt hypothyroidism in nonpregnant adults.

Listen now:

Untreated hypothyroidism can cause serious health complications such as heart failure and myxedema coma. Author Maria Papaleontiou, MD, of the University of Michigan joins JAMA Senior Editor Karen Lasser, MD, MPH, to discuss the current evidence regarding the epidemiology, diagnosis, clinical presen...

09/03/2025

is a condition characterized by the insufficient production of thyroid hormones, commonly affecting women and older adults.

In North America and Europe, its prevalence ranges from 0.3% to 2% but it may affect up to 12% of the population, with higher prevalence in areas with inadequate nutritional iodine levels.

This Review summarizes the epidemiology, pathophysiology, clinical presentation, and treatment of primary overt hypothyroidism in nonpregnant adults.

https://ja.ma/4p36xto

09/03/2025

Staphylococcus aureus bacteremia has a case fatality rate of 15% to 30% and causes 300 000 deaths per year worldwide.

In 2019, Staphylococcus aureus was the leading bacterial cause of death in 135 countries. While the rate of endocarditis in US patients with S aureus bacteremia has declined from more than 50% in 1954 to approximately 12% in 2017, rates of infections involving implantable foreign bodies have increased.

This Review discusses management of S aureus bacteremia.

https://ja.ma/4m1XMNI

09/03/2025

The TARGET 2025 guideline provides recommendations for transparent reporting of observational studies emulating a target trial to estimate causal effects, enhancing clarity and interpretation in the absence of randomized trials.



https://ja.ma/3VwlKFS

09/03/2025

Staphylococcus aureus bacteremia has a case fatality rate of 15% to 30% and causes 300 000 deaths per year worldwide. This Review discusses management of S aureus bacteremia.

This narrative review summarizes current evidence on the epidemiology, pathophysiology, clinical presentation, diagnosis, and treatment of Staphylococcus aureus bacteremia.

09/02/2025

📌 Editor’s Choice from this week's issue of :

➡️ Handling Side Effects of
➡️ Alteplase 4.5 to 24 Hours After Ischemic
➡️ Population Health Colorectal Screening in Adults; and more.

ja.ma/4eRp9GH

09/02/2025

Editorial: Examining trends in colorectal cancer incidence rates and stage at diagnosis can provide insight into whether screening translates into earlier detection of asymptomatic cancers.

https://ja.ma/3VyBBDK

09/02/2025

Colorectal cancer incidence in US adults aged 45 to 49 accelerated to a 12% annual increase from 2019 to 2022, likely indicating earlier detection due to newly lowered screening age recommendations, contrasting with stable long-term trends prior to 2019.

This study examines trends in colorectal cancer incidence among adults younger than 55 years after recommendations for earlier screening.

09/02/2025

RCT: Unsolicited mailed fecal immunochemical test (FIT) outreach was the most effective strategy for promoting colorectal cancer screening in adults aged 45 to 49, outperforming active choice interventions, despite overall low participation rates.

This trial evaluates the most effective population health strategy to promote colorectal cancer screening among average-risk adults aged 45 to 49 years.